Pacific Northwest Prostate Cancer Core Grants for Translational Research
Official title: The Pacific Northwest Prostate Cancer SPORE
Funded at Fred Hutchinson Cancer Center · NIH-11535287 · Data updated 2026-11-12
A collaborative effort across major cancer centers to push new prostate cancer advances from basic science to patient care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 19, 2002 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $211,901 |
| NIH project number | 3P50CA097186-25S1 |
| Project ID | NIH-11535287 on NIH RePORTER |
Who could benefit from this research
✓Could help
American men with prostate cancer who are eligible for novel treatments or neoadjuvant trials developed through this SPORE program.
✕Less likely to help
Patients not eligible for experimental arms or who have conditions outside the trial scope may not directly benefit.
What this research studies
This grant supports translational prostate cancer research across four institutions, combining lab science, clinical studies, and population insights. Researchers focus on understanding how prostate cancer behaves, develops resistance, and responds to new treatments, including CAR T cell approaches and neoadjuvant strategies. The program also emphasizes career development to train researchers who can move discoveries into real-world care for patients with prostate cancer. The collaboration leverages unique preclinical models and clinical trial platforms to test innovative treatment combinations.
Why it matters
Potential benefit: Could lead to new therapies and personalized treatment approaches that reduce prostate cancer morbidity and mortality.
How similar studies have gone: Previous SPORE initiatives have advanced understanding of prostate cancer biology and prompted early-phase trials, with variable success across approaches.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Nelson, Peter S — Fred Hutchinson Cancer Center
- Study coordinator: Nelson, Peter S
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.